Universite Paris-Saclay
36 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 7 name spellings.
7
Ending by 2030
Jan 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 18 to 27, 2026 · next Dec 18
- 2 fees due Jan 7 to 21, 2027 · next Jan 7
- 1 fee due Feb 27, 2027The maintenance fee for Microfluidic Analysis Device and Method (US 10,393,699) comes due Feb 27, 2027. Unpaid by Aug 27, 2027, it lapses early.
- 2 fees due Apr 1 to 8, 2027 · next Apr 1
- 2 fees due May 12 to 28, 2027 · next May 12
- 2 fees due Jul 5 to 28, 2027 · next Jul 5
- 2 fees due Aug 25 to 27, 2027 · next Aug 25
- 4 fees due Sep 10 to 29, 2027 · next Sep 10
- 4 fees due Oct 2 to 26, 2027 · next Oct 2
- 5 fees due Nov 3 to 17, 2027 · next Nov 3
Recent changes
- 9 of the patents on this record were granted since Aug 20, 2026
- 3 terms have ended since Aug 20, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,704,972 | Gemcitabine Derivatives Nanoparticles In force · High confidence | In force | High confidence | |
| US 8,232,518 | Device and Method for Characterizing Surfaces In force · High confidence | In force | High confidence | |
| US 8,178,657 | Polypeptide Sequence Involved in the Modulation of the Immunosuppresive Effect of Viral Proteins In force · High confidence | In force | High confidence | |
| US 11,203,788 | TET2 as a Diagnostic and Pronostic Marker in Hematopoietic Neoplasms In force · High confidence | In force | High confidence | |
| US 10,662,482 | TET2 as a Diagnostic and Pronostic Marker in Hematopoietic Neoplasms In force · High confidence | In force | High confidence | |
| US 8,934,593 | Very High Precision Device for Measuring the Time a Signal is Input In force · High confidence | In force | High confidence | |
| US 9,297,046 | TET2 as a Diagnostic and Pronostic Marker in Hematopoietic Neoplasms In force · High confidence | In force | High confidence | |
| US 9,327,961 | Electrodynamic speaker structure having MEMS technology In force · From the USPTO record | In force | From the USPTO record | |
| US 9,228,962 | Adjustable Cathodoluminescence Detection System and Microscope Employing Such a System In force · Medium confidence | In force | Medium confidence | |
| US 9,389,233 | TET2 as a Diagnostic and Pronostic Marker in Hematopoietic Neoplasms In force · High confidence | In force | High confidence |
Also on record, not counted in the 146: 36 patents in force now held by others · 37 lapsed for an unpaid fee · 13 ended at full term · 1 past the fee grace period. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
67 pending · 30 abandoned · 6 no status recorded